Ghassan Al-jazayrly, MD

home / authors / ghassan-al-jazayrly-md

Articles

A Clinician’s Perspective on ASCO 2001: Going After the Epidermal Growth Factor Receptor

N. Simon Tchekmedyian, MD, FACP;Kalust Ucar, MD, FACP;Eleonor Quan, MD;Howard Cheng, MD;Millie Leung, MD;Ghassan Al-jazayrly, MD;And Andr&, 233; Liem, MD

April 1st 2002

Among the most exciting new anticancer products presented at the 2001 ASCO meeting were new drugs that block the epidermal growth factor receptor (EGFR). About 30% to 90% of carcinomas express high levels of EGFR. These include, among others, head and neck cancer, lung cancer, pancreatic cancer, colon cancer, breast cancer, ovarian cancer, and bladder cancer.

ASCO Update: Chronic Lymphocytic Leukemia

N. Simon Tchekmedyian, MD, FACP;Kalust Ucar, MD, FACP;Eleonor Quan, MD;Ghassan Al-jazayrly, MD;André Liem, MD

March 1st 2002

These reports are written by oncologists from Pacific Shores Medical Group (a large group practice in Long Beach, California). The reports are primarily based on notes taken at the American Society of Clinical Oncology yearly meeting (San Francisco, May 2001). The reports include our impressions (shown in italic type) of the clinical significance of the studies. The information is intended to help you get updated on new developments in oncology. The coverage of the meeting is not meant to be comprehensive, but rather focused on highlights that we consider most interesting or relevant.

ASCO Update: Non-Hodgkin’s Lymphoma

N. Simon Tchekmedyian, MD, FACP;Kalust Ucar, MD, FACP;Eleonor Quan, MD;Ghassan Al-jazayrly, MD;André Liem, MD

February 1st 2002

This and future reports are written by oncologists from Pacific Shores Medical Group (a large group practice in Long Beach, California). The reports are primarily based on notes taken at the American Society of Clinical Oncology